Quarterly ResultAug 5, 2026, 07:16 AM
Kymera Therapeutics Q2 Net Loss $61.2M; KT-621 AD Trial Ahead of Schedule
AI Summary
Kymera Therapeutics reported its second quarter 2026 financial results, showing a reduced net loss of $61.2 million and a significant increase in collaboration revenues to $65.0 million. The company maintains a strong financial position with $1.5 billion in cash, providing a runway into 2029. Operationally, Kymera achieved early completion of enrollment for its KT-621 BROADEN2 Phase 2b atopic dermatitis trial, accelerating data readout to year-end 2026 and planning earlier Phase 3 initiation. Additionally, the company received milestone payments totaling $65 million from its partnerships with Sanofi and Gilead Sciences.
Key Highlights
- Q2 2026 net loss was $61.2 million, an improvement from $76.6 million in Q2 2025.
- Collaboration revenues surged to $65.0 million in Q2 2026 from $11.5 million in Q2 2025.
- Cash, cash equivalents, and investments totaled $1.5 billion as of June 30, 2026.
- Company expects cash runway to extend into 2029.
- KT-621 BROADEN2 Phase 2b AD trial enrollment completed nearly six months early.
- Topline data for KT-621 AD trial now expected by year-end 2026, accelerated from mid-2027.
- Received $20 million milestone from Sanofi for KT-485 Phase 1 trial initiation.
- Received $45 million milestone from Gilead for licensing KT-200.
Price Impact
More from KYMR